Bryn Mawr Capital Management LLC Grows Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Bryn Mawr Capital Management LLC grew its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 358.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 38,898 shares of the company's stock after acquiring an additional 30,420 shares during the period. Bryn Mawr Capital Management LLC's holdings in Novo Nordisk A/S were worth $3,346,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of NVO. Stanley Laman Group Ltd. acquired a new position in Novo Nordisk A/S during the third quarter worth $282,000. Weaver Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 15.3% during the third quarter. Weaver Capital Management LLC now owns 2,298 shares of the company's stock worth $274,000 after purchasing an additional 305 shares in the last quarter. MFA Wealth Advisors LLC raised its position in shares of Novo Nordisk A/S by 184.4% during the 3rd quarter. MFA Wealth Advisors LLC now owns 728 shares of the company's stock worth $87,000 after purchasing an additional 472 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock valued at $215,942,000 after buying an additional 1,796,635 shares in the last quarter. Finally, YHB Investment Advisors Inc. boosted its holdings in Novo Nordisk A/S by 11.3% in the 3rd quarter. YHB Investment Advisors Inc. now owns 3,284 shares of the company's stock worth $391,000 after buying an additional 334 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Up 5.2 %

Shares of NVO traded up $4.33 during mid-day trading on Friday, reaching $88.07. The stock had a trading volume of 15,117,993 shares, compared to its average volume of 9,263,626. Novo Nordisk A/S has a 52-week low of $77.82 and a 52-week high of $148.15. The firm has a market cap of $395.19 billion, a price-to-earnings ratio of 26.77, a P/E/G ratio of 0.90 and a beta of 0.45. The business's fifty day moving average is $86.39 and its 200 day moving average is $108.48. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a $0.7874 dividend. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio is 47.72%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Sunday, December 29th. Cantor Fitzgerald restated an "overweight" rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. Finally, Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.